Research location
Bruchsal
Baden-Wurttemberg, Germany
Advertisement
Research activity in Bruchsal
Baden-Wurttemberg, GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 11 trials and 11 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Bruchsal
11 linked trials · page 1 of 1Use of Diagnostic Measures in Chronic Obstructive Pulmonary Disease (COPD) in Routine Practice and Their Impact on Treatment DecisionsNCT03465332 · 2018-04-19 · 1 site observation
COMPLETED
Observational Study of Obstructive Lung Disease (NOVELTY)NCT02760329 · 2016-07-25 · 1 site observation
COMPLETED
Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary SurgeryNCT02466737 · 2015-09-01 · 1 site observation
ACTIVE_NOT_RECRUITING
SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.NCT01475721 · 2011-11-18 · 1 site observation
COMPLETED
6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years OldNCT01462344 · 2011-11-17 · 1 site observation
COMPLETED
Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary CareNCT01516528 · 2011-11-17 · 1 site observation
COMPLETED
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseNCT01313676 · 2011-01-25 · 1 site observation
COMPLETED
ARI103094-Follow-Up Study for REDUCE Study SubjectsNCT00883909 · 2009-04-09 · 1 site observation
COMPLETED
Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IVNCT00527826 · 2007-11-01 · 1 site observation
COMPLETED
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased RiskNCT00056407 · 2003-03-01 · 1 site observation
COMPLETED
CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.NCT00479739 · 2002-11-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.